Xbrane Biopharma Q1 2024: Approaching an eventful second half of the year
Research Update
2024-05-17
07:45
Redeye returns with a research update following Xbrane’s Q1 report. Sales and EBIT were lower than we had estimated, but end-customer sales grew 30%. The report prompts minor adjustments to our forecasts and valuation.
FE
Filip Einarsson
Analyst Q&A
Closed
Filip Einarsson answered 5 questions.
Disclosures and disclaimers